A5063045773- Diabetes Management and Research
- Diabetes Treatment and Management
- Diabetes and associated disorders
- Peripheral Artery Disease Management
- COVID-19 Clinical Research Studies
- Diabetic Foot Ulcer Assessment and Management
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diagnosis and Treatment of Venous Diseases
- Cerebrovascular and Carotid Artery Diseases
- Cardiovascular Function and Risk Factors
- Liver Disease Diagnosis and Treatment
- Metabolism, Diabetes, and Cancer
- Electrolyte and hormonal disorders
- Blood Pressure and Hypertension Studies
- Pancreatic function and diabetes
- Chronic Kidney Disease and Diabetes
- Lipoproteins and Cardiovascular Health
- Apelin-related biomedical research
- Cardiac Imaging and Diagnostics
- Hormonal Regulation and Hypertension
- Parkinson's Disease Mechanisms and Treatments
- Pharmacology and Obesity Treatment
- Cardiovascular Disease and Adiposity
- Wound Healing and Treatments
Institut Necker Enfants Malades
2022-2025
Université Paris Cité
2016-2025
Inserm
2016-2025
Centre National de la Recherche Scientifique
2022-2025
Hôpital Bichat-Claude-Bernard
2015-2025
Assistance Publique – Hôpitaux de Paris
2016-2025
Sorbonne Paris Cité
2015-2025
Centre de Recherche des Cordeliers
2015-2024
Université Claude Bernard Lyon 1
2013-2024
Sorbonne Université
2009-2023
Coronavirus disease-2019 (COVID-19) is a life-threatening infection caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus. Diabetes has rapidly emerged as major comorbidity for COVID-19 severity. However, phenotypic characteristics of diabetes in patients are unknown. We conducted nationwide multicentre observational study people with hospitalised 53 French centres period 10–31 March 2020. The primary outcome combined tracheal intubation mechanical ventilation...
Abstract Aims/hypothesis This is an update of the results from previous report CORONADO (Coronavirus SARS-CoV-2 and Diabetes Outcomes) study, which aims to describe outcomes prognostic factors in patients with diabetes hospitalised for coronavirus disease-2019 (COVID-19). Methods The initiative a French nationwide multicentre study COVID-19 28-day follow-up. were screened after hospital admission 10 March April 2020. We mainly focused on discharge death within 28 days. Results included 2796...
Abstract Aims To develop and validate a recalibrated prediction model (SCORE2-Diabetes) to estimate the 10-year risk of cardiovascular disease (CVD) in individuals with type 2 diabetes Europe. Methods results SCORE2-Diabetes was developed by extending SCORE2 algorithms using individual-participant data from four large-scale datasets comprising 229 460 participants (43 706 CVD events) without previous CVD. Sex-specific competing risk-adjusted models were used including conventional factors...
Background and Purpose— Admission hyperglycemia is associated with a poor outcome in acute ischemic stroke. How impacts the pathophysiology of stroke remains largely unknown. We investigated how preexisting increases ischemia/reperfusion cerebral injury. Methods— Normoglycemic streptozotocin-treated hyperglycemic rats were subjected to transient middle artery occlusion. Infarct growth brain perfusion assessed by magnetic resonance imaging. Markers platelet, coagulation, neutrophil activation...
Abstract Aim To assess the relationship between body mass index (BMI) classes and early COVID‐19 prognosis in inpatients with type 2 diabetes (T2D). Methods From CORONAvirus‐SARS‐CoV‐2 Diabetes Outcomes (CORONADO) study, we conducted an analysis patients T2D categorized by four BMI subgroups according to World Health Organization classification. Clinical characteristics COVID‐19–related outcomes (i.e. intubation for mechanical ventilation [IMV], death discharge day 7 [D7]) were analysed...
OBJECTIVE Peripheral arterial disease (PAD) is a prognostic marker in cardiovascular disease. The use of Doppler-measured ankle-brachial pressure index (Dop-ABI) for PAD diagnosis limited because time, required training, and costs. We assessed automated oscillometric measurement the (Osc-ABI) by nurses clinical staff. RESEARCH DESIGN AND METHODS Clinical staff obtained Osc-ABI with an device 146 patients (83 diabetes) at time Dop-ABI ultrasound evaluation. RESULTS Measurements were most legs...
Plasma copeptin, a surrogate for vasopressin, was associated with albuminuria in population-based studies. These associations are consistent the effect of vasopressin on observed humans and rodents. The objective this study to determine whether plasma copeptin is an independent marker risk renal events people type 2 diabetes albuminuria.We studied 3,101 participants DIABHYCAR trial (6-year follow-up) albuminuria. A event defined as doubling serum creatinine or development end-stage...
Experimental data support a role for vasopressin in metabolic disorders.We investigated associations of plasma copeptin, surrogate vasopressin, and allelic variations the arginine vasopressin-neurophysin II gene with insulin secretion, sensitivity, risk impaired fasting glucose (IFG) type 2 diabetes mellitus (T2DM).We studied 5110 unrelated French men women from prospective cohort general population (Data Epidemiological Study on Insulin Resistance Syndrome cohort, 9-y follow-up). Six single...
Early in the COVID-19 pandemic, type 2 diabetes (T2D) was marked as a risk factor for severe disease and mortality. Inflammation is central to aetiology of both conditions where variations immune responses can mitigate or aggravate course. Identifying at-risk groups based on immunoinflammatory signatures valuable directing personalised care developing potential targets precision therapy. This observational study characterised immunophenotypic variation associated with severity T2D....
Abstract Aims The 2021 European Society of Cardiology prevention guidelines recommend the use (lifetime) risk prediction models to aid decisions regarding initiation prevention. We aimed update and systematically recalibrate LIFEtime-perspective CardioVascular Disease (LIFE-CVD) model four regions for estimation lifetime CVD apparently healthy individuals. Methods results updated LIFE-CVD (i.e. LIFE-CVD2) were derived using individual participant data from 44 cohorts in 13 countries (687 135...
Plasma copeptin, a surrogate for vasopressin, has been associated with decline in renal function and albuminuria population-based studies as well progression of diabetic nephropathy people type 2 diabetes. We assessed the risk kidney coronary events all-cause mortality plasma copeptin 1 diabetes.Plasma was measured baseline samples GENEDIAB (n = 398; 56% male; mean ± SD age 45 12 years diabetes duration 28 10 years) GENESIS 588; 52% 42 11 years; 27 9 cohorts. Follow-up data were available...
Cardiovascular disease and kidney damage are tightly associated in people with type 2 diabetes. Experimental evidence supports a causal role for vasopressin (or antidiuretic hormone) the development of diabetic (DKD). Plasma copeptin, COOH-terminal portion pre-provasopressin surrogate marker vasopressin, was shown to be positively progression DKD. Here we assessed association plasma copeptin risk cardiovascular events during follow-up two prospective cohorts patients, examined if this could...
Objective: The use of continuous glucose monitoring (CGM) systems and subcutaneous insulin infusion (CSII) devices adhering to the skin can lead reactions. objective was determine prevalence consequences reactions at CGM or CSII sites in a large unbiased population. Research Design Methods: This is cross-sectional multicenter study. All adult patients with diabetes seen consultation over period 7 months using having used system adhesives (in last 10 years) were included filled out...
Abstract Aims Real‐world data are required to support glucagon‐like peptide‐1 receptor agonist use in type 2 diabetes (T2D). SURE France assessed once‐weekly semaglutide adults with T2D real‐world clinical practice. Materials and Methods This multicentre, prospective, open‐label, single‐arm study included ≥1 documented glycated haemoglobin (HbA1c) value ≤12 weeks before initiation. The primary endpoint was HbA1c change from baseline end of (EOS; ~30 weeks). Secondary endpoints EOS body...
Cardiac ischemia is a leading cause of death, especially in diabetic patients. The ischemic heart resistant experimentally to established cardioprotective treatments. New pharmacological approaches cardiac protection are warranted. kallikrein-kinin system involved myocardial ischemia. Respective roles B1 (B1R) and B2 (B2R) receptors remain controversial. We tested whether activation kinin may have therapeutic effect ischemia-reperfusion nondiabetic (NDiab) (Diab) mice. assessed on infarct...
<h3>Objective</h3> ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are widely prescribed in patients with high cardiovascular (CV) risk. However, whether both classes have equivalent effectiveness to prevent CV events remains unclear. The aim of this study was compare the incidence major between ACEI ARB users. <h3>Methods</h3> Reduction Atherothrombosis for Continued Health registry is an observational who enrolled 69 055 individuals Among them, 40 625 (ACEIs 67.9% ARBs...
The pattern of renal function decline prior to cardiovascular (CV) events in type 2 diabetes is not well known. Our aim was describe the association between trajectories and occurrence a CV event.We considered patients with from SURDIAGENE (Survie, Diabete de et Genetique) study (discovery cohort) DIABHYCAR (Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, Ramipril) (replication cohort). Global patterns estimated glomerular filtration rate...
<b><i>Background/Aims:</i></b> In recent days, chronic kidney disease (CKD) is becoming an increasing public health problem. Identification of factors contributing to its progression crucial for designing preventive interventions. Previous studies suggested that chronically high vasopressin deleterious the renal function. We evaluated plasma copeptin, a surrogate vasopressin, as predictor function decline in community cohort....